An investigation into a novel clinical use of a single low dose of insulin in the prevention of excessive cutaneous scarring

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-001259-39-GB

Enrollment

Registered

2005-06-02

Start date

2005-06-30

Completion date

Unknown

Last updated

2019-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Normal scarring Hypertrophic scarring Hypertrophic scarring

Interventions

Trade Name: Insulatard Product Name: Insulatard Pharmaceutical Form: Concentrate for solution for injection Pharmaceutical form of the placebo: Solution

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Heathly subjects having elective bilateral breast reduction surgery. Ages 18 - 65. Caucasian (to exclude racial differences in scarring). Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Diabetes mellitus Patients with a history of hypertrophic or keloid scarring Smokers - impairs wound healing Any systemic illness that could have a theoretical interaction with the insulin administered such as patients with renal or liver disease or endocrine tumours

Design outcomes

Primary

Measure	Time frame
Main Objective: To determine whether local infiltration of insulin to a wound at the time of closure can reduce scarring severity.;Secondary Objective: ;Primary end point(s): A statistically proven reduction in postoperative cutaneous scarring.	—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026